Yesterday’s publication of PriceWaterhouseCooper’s evaluation of the biotechnology industry provides some sobering reading.  Amongst the doom and gloom there’s promise and some pointers for where this industry’s service providers should look for securing and growing Read more...

For young biotechnology companies, attracting seed and early stage funding has become increasingly difficult this year although anecdotal signs of recovery are beginning to emerge. The main reason: venture capital funds have been focusing on their existing portfolio companies who were holding off Read more...